Opdivo, part of a new class of medicines designed to use the body's
own immune system to fight cancer, is already approved to treat
advanced melanoma, a form of lung cancer, kidney cancer, and Hodgkin
lymphoma.
Investors were disappointed last month when Bristol-Myers said it
would not seek accelerated FDA approval for a combination of Opdivo
and another immunotherapy, Yervoy, as an initial treatment for lung
cancer.
The FDA is slated to decide in May whether to approve rival Merck &
Co Inc's combination of immunotherapy Keytruda and chemotherapy for
first-line lung cancer.
(Reporting By Deena Beasley; editing by Diane Craft)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
![](http://archives.lincolndailynews.com/2017/Jan/26/images/ads/current/Symphony_lda_2017.png)
![](http://archives.lincolndailynews.com/2017/Feb/03/images/ads/current/lincolntheatre_sda_031016.png)
![](http://archives.lincolndailynews.com/2016/Aug/26/images/ads/current/ldn_business_directory_small2_2016.png)
|